Regeneron Pharmaceuticals (REGN) Cash from Operations (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Cash from Operations of 813000000.0 for Q2 2026, down 28.96% year-over-year from 1144400000.0 in Q2 2025, and down 24.65% quarter-over-quarter from 1078900000.0 in Q1 2026.
Regeneron Pharmaceuticals (REGN) Cash from Operations (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 813000000.0 for Q2 2026.
- In Q2 2026, Cash from Operations fell 28.96% year-over-year to 813000000.0; the TTM figure through Jun 2026 stood at 4681300000.0 (down 1.31% YoY), while the FY2025 annual figure was 4978900000.0, up 12.63% from the prior year.
- Cash from Operations for Q2 2026 stood at 813000000.0, down from 1078900000.0 in the prior quarter.
- The five-year high for Cash from Operations was 2101700000.0 in Q1 2022, with the low at 354000000.0 in Q2 2024.
- The 5-year median for Cash from Operations is 1129350000.0 (2023), against an average of 1161122222.22.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 81.58% in 2022, then surged 223.28% in 2025.
- Regeneron Pharmaceuticals' Cash from Operations stood at 1719900000.0 in 2022, then plunged by 36.64% to 1089700000.0 in 2023, then rose by 15.89% to 1262800000.0 in 2024, then fell by 7.29% to 1170700000.0 in 2025, then sank by 30.55% to 813000000.0 in 2026.
- Business Quant data shows REGN's Cash from Operations at 813000000.0 in Q2 2026, 1078900000.0 in Q1 2026, and 1170700000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 813.00 Mn |
| Jun 30, 2026 | 813.00 Mn |
| Mar 31, 2026 | 1.08 Bn |
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | 1.62 Bn |
| Sep 30, 2025 | 1.62 Bn |
| Jun 30, 2025 | 1.14 Bn |
| Jun 30, 2025 | 1.14 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.26 Bn |
| Dec 31, 2024 | 1.26 Bn |
| Sep 30, 2024 | 1.29 Bn |
| Sep 30, 2024 | 1.29 Bn |
| Jun 30, 2024 | 354.00 Mn |
| Jun 30, 2024 | 354.00 Mn |
| Mar 31, 2024 | 1.51 Bn |
| Mar 31, 2024 | 1.51 Bn |